Let me start with a question I get more and more frequently from research sites as mRNA continues to expand and be utilized in studies for more—and very different—conditions: “mRNA isn’t gene therapy, so do we need IBC review?”
Different institutions. Different protocols. Same question. And the frequency is increasing.
It’s a fair question. mRNA products do not alter a person’s DNA. They don’t integrate into the genome. They don’t permanently modify genes. So it’s natural to assume this can’t be what the NIH Guidelines, which govern IBC review, were written to address.
But that assumption is where the regulatory story actually begins.
Because the NIH Guidelines are not about “gene therapy.” They are about something broader.
mRNA is not traditional gene therapy
When most people hear “gene therapy,” they think of treatments designed to permanently repair or replace defective genes, such as therapies developed for Duchenne muscular dystrophy or certain inherited retinal disorders. Those therapies are intended to change the genome itself.
mRNA products are different. They do not enter the nucleus to interact with DNA. They do not integrate into the genome. They do not permanently modify genetic material.
That distinction matters scientifically and clinically. It also matters when explaining the technology to research participants. However, it does not resolve the regulatory question under the NIH Guidelines, because “gene therapy” is not the regulatory trigger.
The NIH Guidelines use a different standard
The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules regulate research involving—exactly as the title states—recombinant or synthetic nucleic acid molecules.
Section I-B defines what qualifies. It is a technical definition, and unless you regularly operate in the biosafety space, it requires careful reading. Here is the definition directly from Section I-B of the April 2024 NIH Guidelines:
In the context of the NIH Guidelines, recombinant and synthetic nucleic acids are defined as:
- (i) molecules that a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids;
- (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e., synthetic nucleic acids, or
- (iii) molecules that result from the replication of those described in (i) or (ii) above.
Notice what is not required in that definition: genomic integration.
When sites ask whether mRNA trials require IBC review, the analysis does not begin with “Is this gene therapy?” It begins with a much more precise question: “Does this meet the definition in Section I-B?”
Because that question keeps resurfacing, we went directly to the source.
Advarra’s Executive Director of Biosafety Services and Biosafety Officer Dr. Daniel Eisenman contacted via email the NIH Office of Science Policy (OSP) on Feb. 10, 2026. He asked plainly whether Section I-B applies to clinical trials involving lipid nanoparticles containing mRNA, and whether such trials fall under Section III-C-1, which covers deliberate transfer into human research participants.
The NIH’s email response, received Feb. 17, 2026, was clear. The assistant director for biosafety policy in the Division of Biosafety, Biosecurity, and Emerging Biotechnologies Policy at the National Institutes of Health responded:
“In general, mRNA would be considered to meet the definition of recombinant or synthetic nucleic acids in Section I-B of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Section III-C-1 applies to deliberate transfer of mRNA to human research participants.
That is direct confirmation from the office responsible for promulgating and interpreting the NIH Guidelines.”
Why the question persists
In the field, researchers often focus on what mRNA products do not do: They do not integrate, and they do not permanently alter DNA. From that perspective, it feels reasonable to conclude that the product falls outside of what the Guidelines were designed to regulate.
However, the NIH Guidelines do not require permanent genomic alteration to apply.
Section III-C-1 covers “Experiments Involving the Deliberate Transfer of Recombinant or Synthetic Nucleic Acid Molecules … into One or More Human Research Participants.”
If a study involves the deliberate administration of engineered nucleic acid molecules (genetic material) into human participants—and those molecules can be translated into protein—then it falls squarely within the regulatory framework the Guidelines address.
The trigger is deliberate transfer of recombinant or synthetic nucleic acids into humans. It is not permanent modification of DNA.
Technical perspective: Why mRNA meets the definition
Want to take a deeper dive into the science of mRNA and why these products are considered recombinant or synthetic nucleic acids? Read Dr. Daniel Eisenman’s recent whitepaper explaining how mRNA products are constructed, why they qualify as recombinant or synthetic nucleic acid molecules under Section I-B, and why non-integration or non-replication does not remove them from the definition.
Download the white paper HERE.
So what should sites do?
Returning to the question that keeps coming up: “If it’s not gene therapy, do we need IBC review?”
The definitional answer is yes. mRNA products meet the Section I-B definition of recombinant or synthetic nucleic acid molecules, and deliberate administration to human participants falls under Section III-C-1 of the NIH Guidelines.
That does not mean every mRNA study automatically requires IBC review in every circumstance. Funding source, best practice, and institutional policy still matter. The NIH Guidelines apply based on the nature of the product (in this case mRNA), NIH support to the research site, and also best practice as noted in NIH OSP’s frequently asked questions.
In other words, the regulatory analysis is nuanced. But the definitional question—the one that continues to surface—has the same answer Advarra has been giving to research sites all along: While mRNA based investigational products are not traditional gene therapy, they are considered recombinant or synthetic nucleic acid molecules as defined under Section I-B of the NIH Guidelines. Therefore, the product’s use in humans for research purposes is subject to those Guidelines, including IBC oversight as applicable.
Final thought
As mRNA technology expands into new therapeutic areas, regulatory questions will continue to follow. When terminology evolves faster than the regulations that govern it, confusion is inevitable. The key is returning to the language of the Guidelines themselves and applying it consistently.
It’s not gene therapy.
But yes, it falls under and is subject to the NIH Guidelines.
And that’s why IBC review at your research site or institution may be required.
